

PIN WANG, Ph.D.

Professor of Chemical Engineering & Materials Science
Kaprielian Faculty Fellow of Engineering
University of Southern California
Los Angeles, CA 90089-1211

Tel: (213) 740-0780 • Fax: (213) 740-8053 • E-mail: pinwang@usc.edu
<http://chems.usc.edu/pwgroup>

Professional Preparation

<i>Institution</i>	<i>Field</i>	<i>Degree</i>	<i>Year</i>
University of Sci. & Tech. of China	Material Science & Engineering	B.S.	1997
California Institute of Technology	Chemical Engineering	Ph.D.	2003
California Institute of Technology	NanoSystems Biology	Postdoc	2004

Appointments

2019-present	CSO of Simcere (Leave of Absence from USC)
2014-present	Director, Center for ImmunoEngineering, Viterbi School of Engineering, USC
2014-present	Kaprielian Faculty Fellow of Engineering, USC
2014-present	Professor, Department of Pharmacy and Pharmaceutical Sciences, USC
2014-present	Professor, Department of Biomedical Engineering, USC
2014-present	Professor, Department of Chemical Engineering and Materials Science, USC
2010-2013	Associate Professor, Department of Chemical Engineering and Materials Science, USC
2010-present	Member, USC Norris Comprehensive Cancer Center
2010-present	Member, Joint Center for Translational Medicine
2007-present	Member, West Coast Translational Consortium, Caltech/UCLA/USC
2005-2010	Assistant Professor, Department of Chemical Engineering and Materials Science, USC

Products

Most Closely Related Products (peered reviewed publications):

1. Han, X., Bryson, P., Zhao, Y., Li, S., Cinay, G., Guo, Y., Siriwon, N., Wang, P., Masked chimeric antigen receptor for tumor-specific activation, *Mol. Ther.*, **2017**, 25(1):274-284.
<https://www.ncbi.nlm.nih.gov/pubmed/28129121>
2. Rohrs, J.A., Wang, P., Finley, S.D., Predictive Model of lymphocyte-specific protein tyrosine kinase (LCK) autoregulation, *Cell Mol. Bioeng.*, **2016**, (:351-367).
<https://www.ncbi.nlm.nih.gov/pubmed/27547268>
3. Fang, J., Hu, B., Li, S., Zhang, C., Liu, Y., Wang, P., A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma, *Mol. Ther. Oncolytics*, **2016**, 3:16007.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824564/>
4. Fang, J., Xiao, L., Joo, K.I., Liu, Y., Zhang, C., Liu, S., Conti, P.S., Li, Z., Wang, P., A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice, *Int. J. Cancer*, **2015**, 138, 1013-1023.
<http://onlinelibrary.wiley.com/doi/10.1002/ijc.29831/abstract>
5. Kim, Y.J., Liu, Y., Li, S., Rohrs, J., Zhang, X., Wang, P., Co-eradication of breast cancer cells and cancer stem cells by cross-linked multilamellar liposomes enhances tumor treatment, *Mol. Pharm.*, **2015**, 12(8): 2811-2822.
<https://www.ncbi.nlm.nih.gov/pubmed/26098197>
6. Fang, J., Xiao, L., Joo, K.I., Liu, Y., Zhang, C., Liu, S., Conti, P.S., Li, Z., Wang, P., A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice, *Int. J. Cancer*, **2015**, 138, 1013-1023.
<http://onlinelibrary.wiley.com/doi/10.1002/ijc.29831/abstract>
7. Liu, Y., Kim, Y.J., Ji, M., Fang, J., Siriwon, N., Zhang, L., Wang, P., Enhancing in vitro and in vivo gene delivery of adeno-associated virus type 2 by cell-permeable peptides, *Mol. Ther. Methods & Clinical Development*, **2014**, 1, 12.

- <https://www.ncbi.nlm.nih.gov/pubmed/26015948>
8. Liu, Y., Xiao, L., Joo, K.I., Hu, B., Fang, J., Wang, P., In situ modulation of dendritic cells by injectable thermo-sensitive hydrogels for cancer vaccines in mice, *Biomacromolecules*, **2014**, 15(10):3836-3845.
<http://pubs.acs.org/doi/abs/10.1021/bm501166j>
 9. Joo, K.I., Xiao, L., Liu, S., Liu, Y., Lee, C.L., Conti, P.S., Wong, M.K., Li, Z., Wang, P., Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs, *Biomaterials* **2013**, 34, 3098.
<http://www.sciencedirect.com/science/article/pii/S0142961213000550>
 10. Dai, B., Xiao, L., Bryson, P.D., Wang, P., PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines, *Mol. Ther.*, **2012**, 20, 1800-1809.
 11. Xiao, L., Kim, J., Lim, M., Dai, B., Yang, L., Reed, S.G., Baltimore, D., Wang, P. A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses, *Vaccine*, **2012**, 30, 2570-2581.
<http://www.sciencedirect.com/science/article/pii/S0264410X12001120>
 12. Lei, Y., Lee, C.L., Joo, K.I., Zarzar, J., Liu, Y., Dai, B., Fox, V., Wang, P., Gene editing of human embryonic stem cells via an engineered baculoviral vector carrying zinc finger nucleases, *Mol. Ther.*, **2011**, 19, 942.
<http://www.nature.com/mt/journal/v19/n5/full/mt201112a.html>
 13. Dai, B., Yang, L., Yang, H., Hu, B., Baltimore, D., Wang, P., HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells, *Proc. Natl. Acad. Sci. USA*, **2009**, 106, 20382-20387.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777969/>
 14. Yang, L., Yang, H., Rideout, K., Cho, T., Joo, K., Ziegler, L., Elliot, A., Walls, A., Yu, D., Baltimore, D., Wang, P., Engineered lentivector targeting of dendritic cells for in vivo immunization, *Nat. Biotech.*, **2008**, 26, 326-334.
<http://www.nature.com/nbt/journal/v26/n3/full/nbt1390.html>
 15. Yang, L., Bailey, L., Baltimore, D., Wang, P., Targeting lentiviral vectors to specific cell types in vivo. *Proc. Natl. Acad. Sci. USA*, **2006**, 103, 11479-11484.
<http://www.pnas.org/content/103/31/11479.full>

Other Significant Products (Patents)

1. Wang, P., Yang, L., Baltimore, D., Recombinant retrovirus pseudotyped with a E2 alphavirus glycoprotein, Patent #: US 8,906,359, Dec. 9, **2014**.
2. Baltimore, D., Wang, P., Yang, L., Method of targeted gene delivery using viral vectors, Patent #: US 8,821,856, Sep. 2, **2014**.
3. Wang, P., Kwon, I., Son, S., Tang, Y., Tirrell, D., Site-specific incorporation of amino acids into molecules, Patent #: US 8,518,666, Aug. 27, **2013**.
4. Wang, P., Yang, L., Baltimore, D., Recombinant lentivirus comprising an E2 alphavirus glycoprotein that binds to DC-SIGN, Patent #: US 8,372,390, Feb. 12, **2013**.
5. Wang, P., Yang, L., Baltimore, D., Targeted gene delivery for dendritic cell vaccination, Patent #: US 8,329,162, Dec. 11, **2012**.
6. Yang, L., Baltimore, D., Wang, P., Economou, J., Ribas, A., MART-1 T cell receptors, Patent #: US 8,552,150, Oct. 8, **2012**.

Synergistic Activities

1. For many years, I have been invited to be a reviewer for scientific journals including: ACS Nano, Advanced Materials, Biomaterials, Bioengineering and Biotechnology, Blood, Experimental Hematology, Gene Therapy, Human Gene Therapy, Molecular Therapy, Nature Methods, Molecular Biotechnology, etc.
2. I have been an ad hoc member of NIH GDD study section (2009-2014) and is currently a standing member in 2015. I have been a NSF proposal panelist in CBET divisions. I have been a Chair for the review panel for Southern California CTSI Pilot Funding: Systems Biology and Bioengineering (2011-present). I am review panelist for Ming Hsieh Institute for Research on

Engineering-Medicine for Cancer, Association for International Cancer Research, AIDS FOUNS
from Wellcome Trust.